Rate Video

EBMT 2019 | MRD negativity in ALL

Acute Lymphoblastic Leukemia

Dieter Hoelzer, MD, PhD, from the University of Frankfurt, Frankfurt, Germany, explores the importance of MRD negativity in acute lymphoblastic leukemia (ALL). Dr Hoelzer was speaking at the European Society for Blood and Marrow Transplantation (EBMT) 2019 Annual Meeting, held in Frankfurt, Germany.

Exploring the potential of T-cell therapy for acute lymphoblastic leukemia

Dieter Hoelzer • 12 Jun 2015

New aims and next steps for adult ALL induction therapy

Dieter Hoelzer • 22 Jun 2017

CAR T-cells and BiTEs for hematological malignancies

Two important therapies for ALL

Dieter Hoelzer • 22 Jun 2017

Related Videos

Real-world data on CAR-T therapy for B-ALL

Stephan Grupp • 18 Mar 2021

The future of CAR-T and cellular therapy

Christian Chabannon • 12 Mar 2021

Transplantation during the COVID-19 pandemic

Anna Grassi • 11 Mar 2021

Prolonging remission in AML

Farhad Ravandi • 11 Mar 2021